MedImmune Message Board - Msg: 25087016

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mlkr	10/20/2008 10:40:22 AM
	of 416

New UK facility! Some much-needed good news for the UK: MedImmune has opened a new biologics R&D facility in Cambridge that it says will boost the number of candidate drugs that it can develop each year. MedImmune, which AstraZeneca acquired for $15.6 billion, was merged with Cambridge Antibody Technology last year to become AZ's biologics unit. The new facility is part of the company's strategy to aggressively boost its biologic offerings and deliver an average of one new biologic product per year from 2013. "Today, MedImmune has one of the largest and most diverse biologics product pipelines in the biotech and pharmaceutical industries. We want to maximise our potential to develop new and better medicines, so adequate space and resource for R&D is a real priority for us," said Jane Osbourn, vice president of research, Cambridge.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next